The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects.
Methadone pharmacokinetics were determined in an open-label, within subject study in 16 methadone-maintained, non-HIV-infected subjects prior to and following administration of one lamivudine 150-mg/zidovudine 300-mg combination tablet to determine whether this antiretroviral therapy alters methadone serum concentrations. No significant differences in the mean area under the serum concentration-time curve (AUC(0-24h); 8,753 +/- 4,280 vs. 8,641 +/- 4,431 microg-h/L),oralclearance(CL/F;9.9 +/- 4.9vs. 10.3 +/- 5.5 L/h),oral volume of distribution (Vd/F; 647 +/- 465 vs. 481 +/- 305 L), maximum serum concentration (Cmax; 514 +/- 223 vs. 5,510 +/- 237 microg/L), or terminal elimination half-life (t 1/2; 55.3 +/- 61.0 vs. 35.0 +/- 17.5 h) were detected. These results suggest that methadone dose change is not likely to be necessary for patients treated with lamivudine/zidovudine combination pharmacotherapy.
Rainey
Petrie M
PM
Yale University School of Medicine, New Haven, Conn, USA. pmrainey@u.washington.edu
Friedland
Gerald H
GH
Snidow
Jerry W
JW
McCance-Katz
Elinore F
EF
Mitchell
Susan M
SM
Andrews
Laurie
L
Lane
Barbara
B
Jatlow
Peter
P
D000293:Adolescent; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006679:HIV Seropositivity / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008297:Male; D008691:Methadone / Q000097:blood / Q000493:pharmacokinetics*; D008875:Middle Aged; D009294:Narcotics / Q000493:pharmacokinetics*; D009293:Opioid-Related Disorders / Q000097:blood / Q000534:rehabilitation*; D015215:Zidovudine / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D004338:Drug Combinations; D009294:Narcotics; D019259:Lamivudine; D015215:Zidovudine; D008691:Methadone